pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma
Chinese Academy of
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chinese Academy of clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- China, TAIZHOU, CN
- Employees
- 170
- Programs
- 24
- Drugs
- 538
- Patents
- 4
Chinese Academy of projects
11 ClinicalTrials.gov programs sponsored by Chinese Academy of.
Chinese Academy of has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Carbon Nanoparticle Iron Suspension for Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HNSCC
1 trial -
Decitabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
Dexamethasone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ITP
1 trial -
GlyT-1 inhibitor-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
IIT2024067
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
Iguratimod
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ITP
1 trial -
Iparomlimab and Tuvonralimab Injection (QL1706)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocarcinoma
1 trial -
NMDAE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
2 trials -
NMDAE plus AIFA
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HNSCC
1 trial -
levamisole
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anemia
1 trial
Frequently asked questions
How many clinical projects does Chinese Academy of have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.